

Table S1. Prenatal exposure to triclocarban dysregulated the expression of neurogenesis- and neurotransmitter-related genes in the prefrontal cortices of one-month-old male (part a) and female (part b) mice that as determined by microarray analyses.

a. Males

Gene ontology	Set of genes
Upregulated genes	
neurogenesis-related genes	<i>Artn, Bmp2, Nog, Notch2, Pou4f1 and Sox3</i>
neurotransmitter-related genes	<i>Adra1a, Adra2a, Adrb2, Adrb3, Avpr1b, Brs3, Chrm1, Chrm4, Chrm5, Chrna3, Chrna4, Chrna7, Drd5, Gabbr1, Gabbr2, Gabra1, Gabra6, Gabrb1, Gabrd, Gabrg3, Gabrq, Gabrr1, Gria1, Gria2, Gria3, Grik2, Grin1, Grm3, Grm6, Grm7, Grm8, Grpr, Hcrtr2, Hrh1, Npy2r, Npy5r, Tacr1, and Tacr2</i>
Downregulated genes	
neurogenesis-related genes	<i>Adora1, Alk, Apbb1, Ascl1, Bdnf, Bmp4, Bmp8b, Chrm2, Dcx, Drd2, Dvl3, Erbb2, Gdnf, Gpi1, Grin1, Hes1, Hey1, Mdk, Map2, Ndn, Ndp, Nrg1, Ntf3, Ntn1, Olig2, Pard3, Pax6, Rtn4, Slit2, Stat3, Th and Tnr</i>
neurotransmitter-related genes	<i>Adra1d, Avpr1a, Cckbr, Chrna5, Chrna6, Chrne, Drd2, Gabra2, Gabra5, Gabre, Gcgr, Grm5, Htr2a, Htr3a, Htr4 and Sstr4</i>

b. Females

Gene ontology	Set of genes
Upregulated genes	
neurogenesis-related genes	<i>Bdnf, Chrm2, Efnb1, Egf, Hes1, Neurog1, Notch2, Nrg1, Nrp1, Ntn1, Pafah1b1, Pax5, Pou3f3, S100b, and Shh</i>
neurotransmitter-related genes	<i>Adra1d, Chrne, Drd2, Gabra5, Htr2c, Htr4, Oxtr, Prokr2, Sstr4, Tacr3, and Tspo</i>
Downregulated genes	
neurogenesis-related genes	<i>Adora2a, Ascl1, Bmp2, Cdk5rap2, Cxcl1, Dll1, Drd2, Fgf2, Gdnf, Il3, Neurod1, Neurog2, Nog, Notch1, Nr2e3, Ntf3, Olig2, Pax3, Pou4f1, Sox2, Sox3, and Th</i>
neurotransmitter-related genes	<i>Adra1a, Adra2a, Adrb2, Adrb3, Avpr1a, Brs3, Cckbr, Chrm1, Chrm4, Chrm5, Chrna3, Chrna4, Chrna5, Chrna7, Cnr1, Drd5, Gabbr1, Gabra1, Gabra4, Gabra6, Gabrb1, Gabrd, Gabrg3, Gria1, Gria2, Grik2, Grin1, Grin2a, Grm3, Grm5, Grm6, Grm7, Grm8, Hcrtr2, Hrh1, Htr2a, Tacr1 and Tacr2</i>

Neurogenesis-related genes

Symbol	Description
<i>Adra1a</i>	Adrenergic, alpha-1A-, receptor
<i>Adra1d</i>	Adrenergic, alpha-1D-, receptor
<i>Adra2a</i>	Adrenergic, alpha-2A-, receptor
<i>Adrb2</i>	Adrenergic, beta-2-, receptor, surface
<i>Adrb3</i>	Adrenergic, beta-3-, receptor
<i>Avpr1a</i>	Arginine vasopressin receptor 1A
<i>Avpr1b</i>	Arginine vasopressin receptor 1B
<i>Brs3</i>	Bombesin-like receptor 3
<i>Cckbr</i>	Cholecystokinin B receptor
<i>Chrm1</i>	Cholinergic receptor, muscarinic 1
<i>Chrm4</i>	Cholinergic receptor, muscarinic 4
<i>Chrm5</i>	Cholinergic receptor, muscarinic 5
<i>Chrna3</i>	Cholinergic receptor, nicotinic, alpha 3
<i>Chrna4</i>	Cholinergic receptor, nicotinic, alpha 4
<i>Chrna5</i>	Cholinergic receptor, nicotinic, alpha 5
<i>Chrna6</i>	Cholinergic receptor, nicotinic, alpha 6
<i>Chrna7</i>	Cholinergic receptor, nicotinic, alpha 7
<i>Chrne</i>	Cholinergic receptor, nicotinic, epsilon
<i>Cnr1</i>	Cannabinoid receptor 1 (brain)
<i>Drd1</i>	Dopamine receptor D1
<i>Drd2</i>	Dopamine receptor D2
<i>Drd5</i>	Dopamine receptor D5
<i>Gabbr1</i>	Gamma-aminobutyric acid (GABA) B receptor, 1
<i>Gabbr2</i>	Gamma-aminobutyric acid (GABA) B receptor, 2
<i>Gabra1</i>	Gamma-aminobutyric acid (GABA) A receptor, alpha 1
<i>Gabra2</i>	Gamma-aminobutyric acid (GABA) A receptor, alpha 2
<i>Gabra4</i>	Gamma-aminobutyric acid (GABA) A receptor, alpha 4
<i>Gabra5</i>	Gamma-aminobutyric acid (GABA) A receptor, alpha 5
<i>Gabra6</i>	Gamma-aminobutyric acid (GABA) A receptor, alpha 6
<i>Gabrb1</i>	Gamma-aminobutyric acid (GABA) A receptor, beta 1
<i>Gabrb3</i>	Gamma-aminobutyric acid (GABA) A receptor, beta 3
<i>Gabrd</i>	Gamma-aminobutyric acid (GABA) A receptor, delta
<i>Gabre</i>	Gamma-aminobutyric acid (GABA) A receptor, epsilon
<i>Gabrg1</i>	Gamma-aminobutyric acid (GABA) A receptor, gamma 1
<i>Gabrg2</i>	Gamma-aminobutyric acid (GABA) A receptor, gamma 2
<i>Gabrg3</i>	Gamma-aminobutyric acid (GABA) A receptor, gamma 3
<i>Gabrq</i>	Gamma-aminobutyric acid (GABA) receptor, theta
<i>Gabrr1</i>	Gamma-aminobutyric acid (GABA) receptor, rho 1
<i>Gabrr2</i>	Gamma-aminobutyric acid (GABA) receptor, rho 2
<i>Gcgr</i>	Glucagon receptor
<i>Gria1</i>	Glutamate receptor, ionotropic, AMPA 1
<i>Gria2</i>	Glutamate receptor, ionotropic, AMPA 2
<i>Gria3</i>	Glutamate receptor, ionotropic, AMPA 3
<i>Grik1</i>	Glutamate receptor, ionotropic, kainate 1
<i>Grik2</i>	Glutamate receptor, ionotropic, kainate 2
<i>Grik4</i>	Glutamate receptor, ionotropic, kainate 4
<i>Grik5</i>	Glutamate receptor, ionotropic, kainate 5
<i>Grin1</i>	Glutamate receptor, ionotropic, N-methyl D-aspartate 1
<i>Grin2a</i>	Glutamate receptor, ionotropic, N-methyl D-aspartate 2A
<i>Grin2b</i>	Glutamate receptor, ionotropic, N-methyl D-aspartate 2B

Supplementary material 1 – S1

<i>Grin2c</i>	Glutamate receptor, ionotropic, N-methyl D-aspartate 2C
<i>Grm1</i>	Glutamate receptor, metabotropic 1
<i>Grm3</i>	Glutamate receptor, metabotropic 3
<i>Grm4</i>	Glutamate receptor, metabotropic 4
<i>Grm5</i>	Glutamate receptor, metabotropic 5
<i>Grm6</i>	Glutamate receptor, metabotropic 6
<i>Grm7</i>	Glutamate receptor, metabotropic 7
<i>Grm8</i>	Glutamate receptor, metabotropic 8
<i>Grpr</i>	Gastrin-releasing peptide receptor
<i>Hcrt2</i>	Hypocretin (orexin) receptor 2
<i>Hrh1</i>	Histamine receptor H1
<i>Hrh4</i>	Histamine receptor H4
<i>Htr1a</i>	5-hydroxytryptamine (serotonin) receptor 1A
<i>Htr1b</i>	5-hydroxytryptamine (serotonin) receptor 1B
<i>Htr1d</i>	5-hydroxytryptamine (serotonin) receptor 1D
<i>Htr1f</i>	5-hydroxytryptamine (serotonin) receptor 1F
<i>Htr2a</i>	5-hydroxytryptamine (serotonin) receptor 2A
<i>Htr2c</i>	5-hydroxytryptamine (serotonin) receptor 2C
<i>Htr3a</i>	5-hydroxytryptamine (serotonin) receptor 3A
<i>Htr4</i>	5-hydroxytryptamine (serotonin) receptor 4
<i>Htr7</i>	5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)
<i>Npy2r</i>	Neuropeptide Y receptor Y2
<i>Npy5r</i>	Neuropeptide Y receptor Y5
<i>Ntsr2</i>	Neurotensin receptor 2
<i>Oxtr</i>	Oxytocin receptor
<i>Prokr2</i>	Prokineticin receptor 2
<i>Sctr</i>	Secretin receptor
<i>Sstr1</i>	Somatostatin receptor 1
<i>Sstr2</i>	Somatostatin receptor 2
<i>Sstr4</i>	Somatostatin receptor 4
<i>Tacr1</i>	Tachykinin receptor 1
<i>Tacr2</i>	Tachykinin receptor 2
<i>Tacr3</i>	Tachykinin receptor 3
<i>Tspo</i>	Translocator protein (18kDa)

Neurotransmitter-related genes

Symbol	Description
<i>Ache</i>	Acetylcholinesterase
<i>Adora1</i>	Adenosine A1 receptor
<i>Adora2a</i>	Adenosine A2a receptor
<i>Alk</i>	Anaplastic lymphoma kinase
<i>Apbb1</i>	Amyloid beta (A4) precursor protein-binding, family B, member 1
<i>Apoe</i>	Apolipoprotein E
<i>App</i>	Amyloid beta (A4) precursor protein
<i>Artn</i>	Artemin
<i>Ascl1</i>	Achaete-scute complex homolog 1 (Drosophila)
<i>Bcl2</i>	B-cell leukemia/lymphoma 2
<i>Bdnf</i>	Brain derived neurotrophic factor
<i>Bmp2</i>	Bone morphogenetic protein 2

Supplementary material 1 – S1

<i>Bmp4</i>	Bone morphogenetic protein 4
<i>Bmp8b</i>	Bone morphogenetic protein 8b
<i>Cdk5r1</i>	Cyclin-dependent kinase 5, regulatory subunit 1 (p35)
<i>Cdk5rap2</i>	CDK5 regulatory subunit associated protein 2
<i>Chrm2</i>	Cholinergic receptor, muscarinic 2, cardiac
<i>Creb1</i>	CAMP responsive element binding protein 1
<i>Cxcl1</i>	Chemokine (C-X-C motif) ligand 1
<i>Dcx</i>	Doublecortin
<i>Dlg4</i>	Discs, large homolog 4 (Drosophila)
<i>Dll1</i>	Delta-like 1 (Drosophila)
<i>Drd2</i>	Dopamine receptor D2
<i>Dvl3</i>	Dishevelled 3, dsh homolog (Drosophila)
<i>Efnb1</i>	Ephrin B1
<i>Egf</i>	Epidermal growth factor
<i>Ep300</i>	E1A binding protein p300
<i>ErbB2</i>	V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
<i>Fgf2</i>	Fibroblast growth factor 2
<i>Flna</i>	Filamin, alpha
<i>Gdnf</i>	Glial cell line derived neurotrophic factor
<i>Gpi1</i>	Glucose phosphate isomerase 1
<i>Grin1</i>	Glutamate receptor, ionotropic, NMDA1 (zeta 1)
<i>Hdac4</i>	Histone deacetylase 4
<i>Hes1</i>	Hairy and enhancer of split 1 (Drosophila)
<i>Hey1</i>	Hairy/enhancer-of-split related with YRPW motif 1
<i>Hey2</i>	Hairy/enhancer-of-split related with YRPW motif 2
<i>Heyl</i>	Hairy/enhancer-of-split related with YRPW motif-like
<i>Il3</i>	Interleukin 3
<i>Mdk</i>	Midkine
<i>Mef2c</i>	Myocyte enhancer factor 2C
<i>Kmt2a</i>	Myeloid/lymphoid or mixed-lineage leukemia 1
<i>Map2</i>	Microtubule-associated protein 2
<i>Ndn</i>	Necdin
<i>Ndp</i>	Norrie disease (pseudoglioma) (human)
<i>Neurod1</i>	Neurogenic differentiation 1
<i>Neurog1</i>	Neurogenin 1
<i>Neurog2</i>	Neurogenin 2
<i>Nf1</i>	Neurofibromatosis 1
<i>Nog</i>	Noggin
<i>Notch1</i>	Notch gene homolog 1 (Drosophila)
<i>Notch2</i>	Notch gene homolog 2 (Drosophila)
<i>Nr2e3</i>	Nuclear receptor subfamily 2, group E, member 3
<i>Nrcam</i>	Neuron-glia-CAM-related cell adhesion molecule
<i>Nrg1</i>	Neuregulin 1
<i>Nrp1</i>	Neuropilin 1

Supplementary material 1 – S1

<i>Nrp2</i>	Neuropilin 2
<i>Ntf3</i>	Neurotrophin 3
<i>Ntn1</i>	Netrin 1
<i>Tenm1</i>	Odd Oz/ten-m homolog 1 (Drosophila)
<i>Olig2</i>	Oligodendrocyte transcription factor 2
<i>Pafah1b1</i>	Platelet-activating factor acetylhydrolase, isoform 1b, subunit 1
<i>Pard3</i>	Par-3 (partitioning defective 3) homolog (C. elegans)
<i>Pax3</i>	Paired box gene 3
<i>Pax5</i>	Paired box gene 5
<i>Pax6</i>	Paired box gene 6
<i>Pou3f3</i>	POU domain, class 3, transcription factor 3
<i>Pou4f1</i>	POU domain, class 4, transcription factor 1
<i>Ptn</i>	Pleiotrophin
<i>Rac1</i>	RAS-related C3 botulinum substrate 1
<i>Robo1</i>	Roundabout homolog 1 (Drosophila)
<i>Rtn4</i>	Reticulon 4
<i>S100a6</i>	S100 calcium binding protein A6 (calcyclin)
<i>S100b</i>	S100 protein, beta polypeptide, neural
<i>Shh</i>	Sonic hedgehog
<i>Slit2</i>	Slit homolog 2 (Drosophila)
<i>Sod1</i>	Superoxide dismutase 1, soluble
<i>Sox2</i>	SRY-box containing gene 2
<i>Sox3</i>	SRY-box containing gene 3
<i>Stat3</i>	Signal transducer and activator of transcription 3
<i>Tgfb1</i>	Transforming growth factor, beta 1
<i>Th</i>	Tyrosine hydroxylase
<i>Tnr</i>	Tenascin R
<i>Vegfa</i>	Vascular endothelial growth factor A
<i>Actb</i>	Actin, beta
<i>B2m</i>	Beta-2 microglobulin
<i>Gapdh</i>	Glyceraldehyde-3-phosphate dehydrogenase
<i>Gusb</i>	Glucuronidase, beta
<i>Hsp90ab1</i>	Heat shock protein 90 alpha (cytosolic), class B member 1

Table S2: Primer sets

Primer sets


Target Gene	Source
<i>Ahr</i>	Thermo Fisher Scientific, USA - Mm01291777_m1
<i>Arnt</i>	Thermo Fisher Scientific, USA - Mm00507836_m1
<i>Atg7</i>	Thermo Fisher Scientific, USA - Mm00512209_m1
<i>B2m</i>	Thermo Fisher Scientific, USA - Mm00437762_m1
<i>Bax</i>	Thermo Fisher Scientific, USA - Mm00432051_m1
<i>Bcl2</i>	Thermo Fisher Scientific, USA - Mm00477631_m1
<i>Becn1</i>	Thermo Fisher Scientific, USA - Mm01265461_m1
<i>Car</i>	Thermo Fisher Scientific, USA - Mm01283978_m1
<i>Cyp19a1</i>	Thermo Fisher Scientific, USA - Mm00484049_m1
<i>Cyp1a1</i>	Thermo Fisher Scientific, USA - Mm00487218_m1
<i>Esr1</i>	Thermo Fisher Scientific, USA - Mm00433149_m1
<i>Esr2</i>	Thermo Fisher Scientific, USA - Mm00599821_m1
<i>Gapdh</i>	Thermo Fisher Scientific, USA - Mm05724508_g1
<i>Gper1</i>	Thermo Fisher Scientific, USA - Mm01194815_m1
<i>Gsk3b</i>	Thermo Fisher Scientific, USA - Mm00444911_m1
<i>Hprt</i>	Thermo Fisher Scientific, USA - Mm03024075_m1
<i>Map1lc3a</i>	Thermo Fisher Scientific, USA - Mm00458724_m1
<i>Map1lc3b</i>	Thermo Fisher Scientific, USA - Mm00782868_sH
<i>Nup62</i>	Thermo Fisher Scientific, USA - Mm01700766_m1

Gene-specific primers


Target Gene	Source
<i>Esr1</i>	Thermo Fisher Scientific, USA M Probe – CAACAAATTAACCGAAACCCGCTAACCTAA U Probe - CAACAAATTAACCAAAACCCACTAACCTAA
<i>Esr2</i>	Thermo Fisher Scientific, USA M Probe - TCCAATAAATCTAATTACACGACGCGAAAA U Probe - TCCAATAAATCTAATTACACAACACAAAA
<i>Gper1</i>	Thermo Fisher Scientific, USA M Probe – AAAACAAAAACACCCGCCCGATACCTAAAA U Probe - AAAACAAAAACACCCACCCAATACCTAAAA

Enrichment analyzes – downregulated genes in the prefrontal cortices of one-month-old males that were prenatally exposed to the triclocarban


Curated reactome




GO Cellular Component




GO Molecular Function



KEGG




KEGG pathway – Neuroactive ligand-receptor interaction



Supplementary material 3 – S3

g:Profiler - g:GOSt



version	e104_eg51_p15_3922dba
date	8.11.2021, 14:08:00
organism	mmusculus

g:Profiler

[illegible]

Supplementary material 3 – S3

GO-BP		stats																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							</
-------	--	-------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----


Supplementary material 3 – S3

[illegible][illegible][illegible][illegible]


HP	Term name	Term ID	Padj	$-\log_{10}(p\text{-value})$	HP	Term name	Term ID	Padj	$-\log_{10}(p\text{-value})$
	Ganglioneuroma	HP0003005	6.204×10^{-3}						
	Ganglioneuroblastoma	HP0006747	6.204×10^{-3}						
	Neuropathic of the autonomic nervous system	HP0030450	6.204×10^{-3}						

Enrichment analyzes – downregulated genes in the prefrontal cortices of one-month-old females that were prenatally exposed to the triclocarban


Curated reactome




GO Cellular Component




GO Molecular Function




KEGG




KEGG pathway – Neuroactive ligand-receptor interaction



KEGG pathway – Glutaminergic synapse



g:Profiler - g:GOST






Supplementary material 4 – S4

[illegible]

Supplementary material 4 – S4




[illegible]

Supplementary material 4 – S4




Supplementary material 4 – S4




Enrichment analyzes – upregulated genes in the prefrontal cortices of one-month-old males that were prenatally exposed to the triclocarban**Curated reactome****GO Cellular Component****GO Molecular Function**


KEGG




KEGG pathway – Neuroactive ligand-receptor interaction




KEGG pathway – Glutaminergic synapse



KEGG pathway – GABAergic synapse



g:Profiler - g:GOST





GO:MF		stats																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
-------	--	-------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Supplementary material 5 – S5


GO BP		stats																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						
-------	--	-------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Supplementary material 5 – S5




Enrichment analyzes – upregulated genes in the prefrontal cortices of one-month-old females that were prenatally exposed to the triclocarban


Curated reactome



GO Cellular Component




GO Molecular Function




Supplementary material 6 – S6

KEGG



g:Profiler - g:GOSt

[illegible]

Supplementary material 6 – S6

[illegible]

Supplementary material 6 – S6

[illegible]

KEGG		stats																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
Term name	Term ID	P _{adj}	$-\log_{10}(P_{adj})$	BCR	CD40	ETBR	ESR	IL6	IL6R	IL6R2	IL6R3	IL6R4	IL6R5	IL6R6	IL6R7	IL6R8	IL6R9	IL6R10	IL6R11	IL6R12	IL6R13	IL6R14	IL6R15	IL6R16	IL6R17	IL6R18	IL6R19	IL6R20	IL6R21	IL6R22	IL6R23	IL6R24	IL6R25	IL6R26	IL6R27	IL6R28	IL6R29	IL6R30	IL6R31	IL6R32	IL6R33	IL6R34	IL6R35	IL6R36	IL6R37	IL6R38	IL6R39	IL6R40	IL6R41	IL6R42	IL6R43	IL6R44	IL6R45	IL6R46	IL6R47	IL6R48	IL6R49	IL6R50	IL6R51	IL6R52	IL6R53	IL6R54	IL6R55	IL6R56	IL6R57	IL6R58	IL6R59	IL6R60	IL6R61	IL6R62	IL6R63	IL6R64	IL6R65	IL6R66	IL6R67	IL6R68	IL6R69	IL6R70	IL6R71	IL6R72	IL6R73	IL6R74	IL6R75	IL6R76	IL6R77	IL6R78	IL6R79	IL6R80	IL6R81	IL6R82	IL6R83	IL6R84	IL6R85	IL6R86	IL6R87	IL6R88	IL6R89	IL6R90	IL6R91	IL6R92	IL6R93	IL6R94	IL6R95	IL6R96	IL6R97	IL6R98	IL6R99	IL6R100	IL6R101	IL6R102	IL6R103	IL6R104	IL6R105	IL6R106	IL6R107	IL6R108	IL6R109	IL6R110	IL6R111	IL6R112	IL6R113	IL6R114	IL6R115	IL6R116	IL6R117	IL6R118	IL6R119	IL6R120	IL6R121	IL6R122	IL6R123	IL6R124	IL6R125	IL6R126	IL6R127	IL6R128	IL6R129	IL6R130	IL6R131	IL6R132	IL6R133	IL6R134	IL6R135	IL6R136	IL6R137	IL6R138	IL6R139	IL6R140	IL6R141	IL6R142	IL6R143	IL6R144	IL6R145	IL6R146	IL6R147	IL6R148	IL6R149	IL6R150	IL6R151	IL6R152	IL6R153	IL6R154	IL6R155	IL6R156	IL6R157	IL6R158	IL6R159	IL6R160	IL6R161	IL6R162	IL6R163	IL6R164	IL6R165	IL6R166	IL6R167	IL6R168	IL6R169	IL6R170	IL6R171	IL6R172	IL6R173	IL6R174	IL6R175	IL6R176	IL6R177	IL6R178	IL6R179	IL6R180	IL6R181	IL6R182	IL6R183	IL6R184	IL6R185	IL6R186	IL6R187	IL6R188	IL6R189	IL6R190	IL6R191	IL6R192	IL6R193	IL6R194	IL6R195	IL6R196	IL6R197	IL6R198	IL6R199	IL6R200	IL6R201	IL6R202	IL6R203	IL6R204	IL6R205	IL6R206	IL6R207	IL6R208	IL6R209	IL6R210	IL6R211	IL6R212	IL6R213	IL6R214	IL6R215	IL6R216	IL6R217	IL6R218	IL6R219	IL6R220	IL6R221	IL6R222	IL6R223	IL6R224	IL6R225	IL6R226	IL6R227	IL6R228	IL6R229	IL6R230	IL6R231	IL6R232	IL6R233	IL6R234	IL6R235	IL6R236	IL6R237	IL6R238	IL6R239	IL6R240	IL6R241	IL6R242	IL6R243	IL6R244	IL6R245	IL6R246	IL6R247	IL6R248	IL6R249	IL6R250	IL6R251	IL6R252	IL6R253	IL6R254	IL6R255	IL6R256	IL6R257	IL6R258	IL6R259	IL6R260	IL6R261	IL6R262	IL6R263	IL6R264	IL6R265	IL6R266	IL6R267	IL6R268	IL6R269	IL6R270	IL6R271	IL6R272	IL6R273	IL6R274	IL6R275	IL6R276	IL6R277	IL6R278	IL6R279	IL6R280	IL6R281	IL6R282	IL6R283	IL6R284	IL6R285	IL6R286	IL6R287	IL6R288	IL6R289	IL6R290	IL6R291	IL6R292	IL6R293	IL6R294	IL6R295	IL6R296	IL6R297	IL6R298	IL6R299	IL6R300	IL6R301	IL6R302	IL6R303	IL6R304	IL6R305	IL6R306	IL6R307	IL6R308	IL6R309	IL6R310	IL6R311	IL6R312	IL6R313	IL6R314	IL6R315	IL6R316	IL6R317	IL6R318	IL6R319	IL6R320	IL6R321	IL6R322	IL6R323	IL6R324	IL6R325	IL6R326	IL6R327	IL6R328	IL6R329	IL6R330	IL6R331	IL6R332	IL6R333	IL6R334	IL6R335	IL6R336	IL6R337	IL6R338	IL6R339	IL6R340	IL6R341	IL6R342	IL6R343	IL6R344	IL6R345	IL6R346	IL6R347	IL6R348	IL6R349	IL6R350	IL6R351	IL6R352	IL6R353	IL6R354	IL6R355	IL6R356	IL6R357	IL6R358	IL6R359	IL6R360	IL6R361	IL6R362	IL6R363	IL6R364	IL6R365	IL6R366	IL6R367	IL6R368	IL6R369	IL6R370	IL6R371	IL6R372	IL6R373	IL6R374	IL6R375	IL6R376	IL6R377	IL6R378	IL6R379	IL6R380	IL6R381	IL6R382	IL6R383	IL6R384	IL6R385	IL6R386	IL6R387	IL6R388	IL6R389	IL6R390	IL6R391	IL6R392	IL6R393	IL6R394	IL6R395	IL6R396	IL6R397	IL6R398	IL6R399	IL6R400	IL6R401	IL6R402	IL6R403	IL6R404	IL6R405	IL6R406	IL6R407	IL6R408	IL6R409	IL6R410	IL6R411	IL6R412	IL6R413	IL6R414	IL6R415	IL6R416	IL6R417	IL6R418	IL6R419	IL6R420	IL6R421	IL6R422	IL6R423	IL6R424	IL6R425	IL6R426	IL6R427	IL6R428	IL6R429	IL6R430	IL6R431	IL6R432	IL6R433	IL6R434	IL6R435	IL6R436	IL6R437	IL6R438	IL6R439	IL6R440	IL6R441	IL6R442	IL6R443	IL6R444	IL6R445	IL6R446	IL6R447	IL6R448	IL6R449	IL6R450	IL6R451	IL6R452	IL6R453	IL6R454	IL6R455	IL6R456	IL6R457	IL6R458	IL6R459	IL6R460	IL6R461	IL6R462	IL6R463	IL6R464	IL6R465	IL6R466	IL6R467	IL6R468	IL6R469	IL6R470	IL6R471	IL6R472	IL6R473	IL6R474	IL6R475	IL6R476	IL6R477	IL6R478	IL6R479	IL6R480	IL6R481	IL6R482	IL6R483	IL6R484	IL6R485	IL6R486	IL6R487	IL6R488	IL6R489	IL6R490	IL6R491	IL6R492	IL6R493	IL6R494	IL6R495	IL6R496	IL6R497	IL6R498	IL6R499	IL6R500	IL6R501	IL6R502	IL6R503	IL6R504	IL6R505	IL6R506	IL6R507	IL6R508	IL6R509	IL6R510	IL6R511	IL6R512	IL6R513	IL6R514	IL6R515	IL6R516	IL6R517	IL6R518	IL6R519	IL6R520	IL6R521	IL6R522	IL6R523	IL6R524	IL6R525	IL6R526	IL6R527	IL6R528	IL6R529	IL6R530	IL6R531	IL6R532	IL6R533	IL6R534	IL6R535	IL6R536	IL6R537	IL6R538	IL6R539	IL6R540	IL6R541	IL6R542	IL6R543	IL6R544	IL6R545	IL6R546	IL6R547	IL6R548	IL6R549	IL6R550	IL6R551	IL6R552	IL6R553	IL6R554	IL6R555	IL6R556	IL6R557	IL6R558	IL6R559	IL6R560	IL6R561	IL6R562	IL6R563	IL6R564	IL6R565	IL6R566	IL6R567	IL6R568	IL6R569	IL6R570	IL6R571	IL6R572	IL6R573	IL6R574	IL6R575	IL6R576	IL6R577	IL6R578	IL6R579	IL6R580	IL6R581	IL6R582	IL6R583	IL6R584	IL6R585	IL6R586	IL6R587	IL6R588	IL6R589	IL6R590	IL6R591	IL6R592	IL6R593	IL6R594	IL6R595	IL6R596	IL6R597	IL6R598	IL6R599	IL6R600	IL6R601	IL6R602	IL6R603	IL6R604	IL6R605	IL6R606	IL6R607	IL6R608	IL6R609	IL6R610	IL6R611	IL6R612	IL6R613	IL6R614	IL6R615	IL6R616	IL6R617	IL6R618	IL6R619	IL6R620	IL6R621	IL6R622	IL6R623	IL6R624	IL6R625	IL6R626	IL6R627	IL6R628	IL6R629	IL6R630	IL6R631	IL6R632	IL6R633	IL6R634	IL6R635	IL6R636	IL6R637	IL6R638	IL6R639	IL6R640	IL6R641	IL6R642	IL6R643	IL6R644	IL6R645	IL6R646	IL6R647	IL6R648	IL6R649	IL6R650	IL6R651	IL6R652	IL6R653	IL6R654	IL6R655	IL6R656	IL6R657	IL6R658	IL6R659	IL6R660	IL6R661	IL6R662	IL6R663	IL6R664	IL6R665	IL6R666	IL6R667	IL6R668	IL6R669	IL6R670	IL6R671	IL6R672	IL6R673	IL6R674	IL6R675	IL6R676	IL6R677	IL6R678	IL6R679	IL6R680	IL6R681	IL6R682	IL6R683	IL6R684	IL6R685	IL6R686	IL6R687	IL6R688	IL6R689	IL6R690	IL6R691	IL6R692	IL6R693	IL6R694	IL6R695	IL6R696	IL6R697	IL6R698	IL6R699	IL6R700	IL6R701	IL6R702	IL6R703	IL6R704	IL6R705	IL6R706	IL6R707	IL6R708	IL6R709	IL6R710	IL6R711	IL6R712	IL6R713	IL6R714	IL6R715	IL6R716	IL6R717	IL6R718	IL6R719	IL6R720	IL6R721	IL6R722	IL6R723	IL6R724	IL6R725	IL6R726	IL6R727	IL6R728	IL6R729	IL6R730	IL6R731	IL6R732	IL6R733	IL6R734	IL6R735	IL6R736	IL6R737	IL6R738	IL6R739	IL6R740	IL6R741	IL6R742	IL6R743	IL6R744	IL6R745	IL6R746	IL6R747	IL6R748	IL6R749	IL6R750	IL6R751	IL6R752	IL6R753	IL6R754	IL6R755	IL6R756	IL6R757	IL6R758	IL6R759	IL6R760	IL6R761	IL6R762	IL6R763	IL6R764	IL6R765	IL6R766	IL6R767	IL6R768	IL6R769	IL6R770	IL6R771	IL6R772	IL6R773	IL6R774	IL6R775	IL6R776	IL6R777	IL6R778	IL6R779	IL6R780	IL6R781	IL6R782	IL6R783	IL6R784	IL6R785	IL6R786	IL6R787	IL6R788	IL6R789	IL6R790	IL6R791	IL6R792	IL6R793	IL6R794	IL6R795	IL6R796	IL6R797	IL6R798	IL6R799	IL6R800	IL6R801	IL6R802	IL6R803	IL6R804	IL6R805	IL6R806	IL6R807	IL6R808	IL6R809	IL6R810	IL6R811	IL6R812	IL6R813	IL6R814	IL6R815	IL6R816	IL6R817	IL6R818	IL6R819	IL6R820	IL6R821	IL6R822	IL6R823	IL6R824	IL6R825	IL6R826	IL6R827	IL6R828	IL6R829	IL6R830	IL6R831	IL6R832	IL6R833	IL6R834	IL6R835	IL6R836	IL6R837	IL6R838	IL6R839	IL6R840	IL6R841	IL6R842	IL6R843	IL6R844	IL6R845	IL6R846	IL6R847	IL6R848	IL6R849	IL6R850	IL6R851	IL6R852	IL6R853	IL6R854	IL6R855	IL6R856	IL6R857	IL6R858	IL6R859	IL6R860	IL6R861	IL6R862	IL6R863	IL6R864	IL6R865	IL6R866	IL6R867	IL6R868	IL6R869	IL6R870	IL6R871	IL6R872	IL6R873	IL6R874	IL6R875	IL6R876	IL6R877	IL6R878	IL6R879	IL6R880	IL6R881	IL6R882	IL6R883	IL6R884	IL6R885	IL6R886	IL6R887	IL6R888	IL6R889	IL6R890	IL6R891	IL6R892	IL6R893	IL6R894	IL6R895	IL6R896	IL6R897	IL6R898	IL6R899	IL6R900	IL6R901	IL6R902	IL6R903	IL6R904	IL6R905	IL6R906	IL6R907	IL6R908	IL6R909	IL6R910	IL6R911	IL6R912	IL6R913	IL6R914	IL6R915	IL6R916	IL6R917	IL6R918	IL6R919	IL6R920	IL6R921	IL6R922	IL6R923	IL6R924	IL6R925	IL6R926	IL6R927	IL6R928	IL6R929	IL6R930	IL6R931	IL6R932	IL6R933	IL6R934	IL6R935	IL6R936	IL6R937	IL6R938	IL6R939	IL6R940	IL6R941	IL6R942	IL6R943	IL6R944	IL6R945	IL6R946	IL6R947	IL6R948	IL6R949	IL6R950	IL6R951	IL6R952	IL6R953	IL6R954	IL6R955	IL6R956	IL6R957	IL6R958	IL6R959	IL6R960	IL6R961	IL6R962	IL6R963	IL6R964	IL6R965	IL6R966	IL6R967	IL6R968	IL6R969	IL6R970	IL6R971	IL6R972	IL6R973	IL6R974	IL6R975	IL6R976	IL6R977	IL6R978	IL6R979	IL6R980	IL6R981	IL6R982	IL6R983	IL6R984	IL6R985	IL6R986	IL6R987	IL6R988	IL6R989	IL6R990	IL6R991	IL6R992	IL6R993	IL6R994	IL6R995	IL6R996	IL6R997	IL6R998	IL6R999	IL6R1000	IL6R1001	IL6R1002	IL6R1003	IL6R1004	IL6R1005	IL6R1006	IL6R1007	IL6R1008	IL6R1009	IL6R1010	IL6R1011	IL6R1012	IL6R1013	IL6R1014	IL6R1015	IL6R1016	IL6R1017	IL6R1018	IL6R1019	IL6R1020	IL6R1021	IL6R1022	IL6R1023	IL6R1024	IL6R1025	IL6R1026	IL6R1027	IL6R1028	IL6R1029	IL6R1030	IL6R1031	IL6R1032	IL6R1033	IL6R1034	IL6R1035	IL6R1036	IL6R1037	IL6R1038	IL6R1039	IL6R1040	IL6R1041	IL6R1042	IL6R1043	IL6R1044	IL6R1045	IL6R1046	IL6R1047	IL6R1048	IL6R1049	IL6R1050	IL6R1051	IL6R1052	IL6R1053	IL6R1054	IL6R1055	IL6R1056	IL6R1057	IL6R1058	IL6R1059	IL6R1060	IL6R1061	IL6R1062	IL6R1063	IL6R1064	IL6R1065	IL6R1066	IL6R1067	IL6R1068	IL6R1069	IL6R1070	IL6R1071	IL6R1072	IL6R1073	IL6R1074	IL6R1075	IL6R1076	IL6R1077	IL6R1078	IL6R1079	IL6R1080	IL6R1081	IL6R1082	IL6R1083	IL6R1084	IL6R1085	IL6R1086	IL6R1087	IL6R1088	IL6R1089	IL6R1090	IL6R1091	IL6R1092	IL6R1093	IL6R1094	IL6R1095	IL6R1096	IL6R1097	IL6R1098	IL6R1099	IL6R1100	IL6R1101	IL6R1102	IL6R1103	IL6R1104	IL6R1105	IL6R1106	IL6R1107	IL6R1108	IL6R1109	IL6R1110	IL6R1111	IL6R1112	IL6R1113	IL6R1114	IL6R1115

[illegible][illegible]

Specificity description of antibodies used in the western blot. The descriptions are provided by the suppliers and the text is derived from datasheets dedicated to particular antibodies

1. Rabbit polyclonal anti-BECN1 antibody (sc-11427)

BECN1 (H-300) is recommended for detection of BECN1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100- 1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- 1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

BECN1 (H-300) is also recommended for detection of BECN1 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for BECN1 siRNA (h): sc-29797, BECN1 siRNA (m): sc-29798, BECN1 shRNA Plasmid (h): sc-29797-SH, BECN1 shRNA Plasmid (m): sc-29798-SH, BECN1 shRNA (h) Lentiviral Particles: sc-29797-V and BECN1 shRNA (m) Lentiviral Particles: sc-29798-V.

Molecular Weight of BECN1: 60 kDa.

Positive Controls: BECN1 (m): 293T Lysate: sc-125053, MCF7 whole cell lysate: sc-2206 or NIH/3T3 whole cell lysate: sc-2210.

2. Mouse monoclonal anti-β-actin antibody (sc-47778)

β-Actin (C4) is recommended for detection of β-Actin of mouse, rat, human, avian, bovine, canine, porcine, rabbit, Dictyostelium discoideum and Physarum polycephalum origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffinembedded sections) (starting dilution 1:50, dilution range 1:50- 1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); may cross-react with all six known isoforms of Actin in higher vertebrates (including cytoplasmic β- and γ-Actin isoforms, skeletal, cardiac, and vascular α-Actin isoforms, and enteric γ-Actin isoform).

Suitable for use as control antibody for β-Actin siRNA (h): sc-108069, β-Actin siRNA (m): sc-108070, β-Actin siRNA (r): sc-156106, β-Actin shRNA Plasmid (h): sc-108069-SH, β-Actin shRNA Plasmid (m): sc-108070-SH, β-Actin shRNA Plasmid (r): sc-156106-SH, β-Actin shRNA (h) Lentiviral Particles: sc-108069-V, β-Actin shRNA (m) Lentiviral Particles: sc-108070-V and β-Actin shRNA (r) Lentiviral Particles: sc-156106-V.

β-Actin (C4) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of β-Actin/C-terminal region of β-Actin: 43/15 kDa.

3. Mouse monoclonal anti-MAP1LC3AB antibody (sc-398822)

MAP LC3α/b (G-4) is recommended for detection of MAP LC3α and MAP LC3b of mouse, rat and human origin and MAP LC3b2 of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100- 1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- 1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30- 1:3000).

Suitable for use as control antibody for MAP LC3α/b siRNA (m): sc-156052, MAP LC3α/b shRNA Plasmid (m): sc-156052-SH and MAP LC3α/b shRNA (m) Lentiviral Particles: sc-156052-V.

Molecular Weight of MAP LC3α isoforms: 15/18 kDa.

Molecular Weight of MAP LC3b: 15 kDa.

Positive Controls: HT-1080 whole cell lysate: sc-364183, Saos-2 cell lysate: sc-2235 or U-251-MG whole cell lysate: sc-364176.

4. Mouse monoclonal anti-nucleoporin p62 antibody (sc-48373)

Nucleoporin p62 (C-9) is recommended for detection of nucleoporin p62 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffinembedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for nucleoporin p62 siRNA (h): sc-36107, nucleoporin p62 siRNA (m): sc-36108, nucleoporin p62 shRNA Plasmid (h): sc-36107-SH, nucleoporin p62 shRNA Plasmid (m): sc-36108-SH, nucleoporin p62 shRNA (h) Lentiviral Particles: sc-36107-V and nucleoporin p62 shRNA (m) Lentiviral Particles: sc-36108-V.

Molecular Weight of nucleoporin p62: 62 kDa.

5. Rabbit polyclonal anti-GPR30 antibody (sc-134576)

GPR30 (H-300) is recommended for detection of GPR30 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

GPR30 (H-300) is also recommended for detection of GPR30 in additional species, including canine and bovine. GPR30 (H-300) is also recommended for detection of GPR30 in additional species, including canine and bovine.

Suitable for use as control antibody for GPR30 siRNA (h): sc-60743, GPR30 siRNA (m): sc-60744, GPR30 siRNA (r): sc-156143, GPR30 shRNA Plasmid (h): sc-60743-SH, GPR30 shRNA Plasmid (m): sc-60744-SH, GPR30 shRNA Plasmid (r): sc-156143-SH, GPR30 shRNA (h) Lentiviral Particles: sc-60743-V, GPR30 shRNA (m) Lentiviral Particles: sc-60744-V and GPR30 shRNA (r) Lentiviral Particles: sc-156143-V.

Molecular Weight of GPR30: 38 kDa.

6. Mouse monoclonal anti-CYP1A1 antibody (sc-25304)

CYP1A1 (B-4) is recommended for detection of CYP1A1 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:500), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for CYP1A1 siRNA (h): sc-41483, CYP1A1 siRNA (m): sc-41484, CYP1A1 siRNA (r): sc-270346, CYP1A1 shRNA Plasmid (h): sc-41483-SH, CYP1A1 shRNA Plasmid (m): sc-41484-SH, CYP1A1 shRNA Plasmid (r): sc-270346-SH, CYP1A1 shRNA (h) Lentiviral Particles: sc-41483-V, CYP1A1 shRNA (m) Lentiviral Particles: sc-41484-V and CYP1A1 shRNA (r) Lentiviral Particles: sc-270346-V.

Molecular Weight of CYP1A1: 56 kDa.

7. Rabbit polyclonal anti-GSK-3 β antibody (sc-9166)

GSK-3 β (H-76) is recommended for detection of GSK-3 β of mouse, rat, human, *Xenopus laevis* and zebrafish origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

GSK-3 β (H-76) is also recommended for detection of GSK-3 β in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for GSK-3 β siRNA (h): sc-35527, GSK-3 β siRNA (m): sc-35525, GSK-3 β shRNA Plasmid (h): sc-35527-SH, GSK-3 β shRNA Plasmid (m): sc-35525-SH, GSK-3 β shRNA (h) Lentiviral Particles: sc-35527-V and GSK-3 β shRNA (m) Lentiviral Particles: sc-35525-V.

Molecular Weight of GSK-3 β : 47 kDa.

Positive Controls: K-562 whole cell lysate: sc-2203, Jurkat whole cell lysate: sc-2204 or HeLa whole cell lysate: sc-2200.

8. Rabbit polyclonal anti-ESR1 antibody (sc-7207)

ER α (H-184) is recommended for detection of estrogen receptor α of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for ER α siRNA (h): sc-29305 and ER α siRNA (m): sc-29306.

ER α (H-184) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of ER α : 66 kDa.

Positive Controls: MCF7 whole cell lysate: sc-2206, human breast carcinoma: sc-4260 WB.

9. Goat polyclonal anti-ESR2 antibody (sc-6822)

ER β (L-20) is recommended for detection of ER β of human and, to a lesser extent, mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

ER β (L-20) is also recommended for detection of ER β in additional species, including canine.

Suitable for use as control antibody for ER β siRNA (h): sc-35325, ER β siRNA (m): sc-35326, ER β shRNA Plasmid (h): sc-35325-SH, ER β shRNA Plasmid (m): sc-35326-SH, ER β shRNA (h) Lentiviral Particles: sc-35325-V and ER β shRNA (m) Lentiviral Particles: sc-35326-V.

ER β (L-20) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of ER β : 56 kDa.

10. Goat polyclonal anti-AHR antibody (sc-8088)

Ah Receptor (N-19) is recommended for detection of Ah Receptor of mouse, rat, human and zebrafish origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-

Supplementary material 7 – S7

2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Ah Receptor (N-19) is also recommended for detection of Ah Receptor in additional species, including canine, bovine and porcine.

Suitable for use as control antibody for Ah Receptor siRNA (h): sc-29654, Ah Receptor siRNA (m): sc-29655, Ah Receptor shRNA Plasmid (h): sc-29654-SH, Ah Receptor shRNA Plasmid (m): sc-29655-SH, Ah Receptor shRNA (h) Lentiviral Particles: sc-29654-V and Ah Receptor shRNA (m) Lentiviral Particles: sc-29655-V.

Ah Receptor (N-19) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight (predicted) of Ah Receptor: 96 kDa.

Molecular Weight (observed) of Ah Receptor: 122 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200.

11. Rabbit polyclonal anti-ARNT antibody (sc-5580)

Arnt 1 (H-172) is recommended for detection of Arnt 1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Arnt 1 (H-172) is also recommended for detection of Arnt 1 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for Arnt 1 siRNA (h): sc-29733, Arnt 1 siRNA (m): sc-29734, Arnt 1 shRNA Plasmid (h): sc-29733-SH, Arnt 1 shRNA Plasmid (m): sc-29734-SH, Arnt 1 shRNA (h) Lentiviral Particles: sc-29733-V and Arnt 1 shRNA (m) Lentiviral Particles: sc-29734-V.

Arnt 1 (H-172) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of Arnt 1: 95 kDa.

12. Mouse monoclonal anti-BCL-2 antibody (sc-7382)

Bcl-2 (C-2) is recommended for detection of Bcl-2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10⁶ cells).

Suitable for use as control antibody for Bcl-2 siRNA (h): sc-29214, Bcl-2 siRNA (m): sc-29215, Bcl-2 shRNA Plasmid (h): sc-29214-SH, Bcl-2 shRNA Plasmid (m): sc-29215-SH, Bcl-2 shRNA (h) Lentiviral Particles: sc-29214-V and Bcl-2 shRNA (m) Lentiviral Particles: sc-29215-V.

Molecular Weight of Bcl-2: 26 kDa.

13. Mouse monoclonal anti-BAX antibody (sc-7480)

Bax (B-9) is recommended for detection of Bax α and Bax β of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-

Supplementary material 7 – S7

1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10⁶ cells).

Suitable for use as control antibody for Bax siRNA (h): sc-29212, Bax siRNA (m): sc-29213, Bax shRNA Plasmid (h): sc-29212-SH, Bax shRNA Plasmid (m): sc-29213-SH, Bax shRNA (h) Lentiviral Particles: sc-29212-V and Bax shRNA (m) Lentiviral Particles: sc-29213-V.

Molecular Weight of Bax: 23 kDa.

Positive Controls: Raji whole cell lysate: sc-364236, NAMALWA cell lysate: sc-2234 or Jurkat whole cell lysate: sc-2204.

14. Mouse monoclonal anti-ATG7 antibody (sc-376212)

ATG7 (B-9) is recommended for detection of ATG7 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100- 1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30- 1:3000).

Suitable for use as control antibody for ATG7 siRNA (h): sc-41447, ATG7 siRNA (m): sc-41448, ATG7 shRNA Plasmid (h): sc-41447-SH, ATG7 shRNA Plasmid (m): sc-41448-SH, ATG7 shRNA (h) Lentiviral Particles: sc-41447-V and ATG7 shRNA (m) Lentiviral Particles: sc-41448-V.

Molecular Weight of ATG7: 71 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200, Jurkat whole cell lysate: sc-2204 or Caki-1 cell lysate: sc-2224.

15. Polyclonal rabbit anti-constitutive androstane receptor antibody (ab-228767)

Product name: Anti-Constitutive androstane receptor antibody

Description: Rabbit polyclonal to Constitutive androstane receptor

Host species: Rabbit Tested applications

Suitable for: WB Species reactivity

Reacts with: Mouse

Predicted to work with: Human, Chimpanzee, Rhesus monkey

Immunogen: Recombinant fragment within Human Constitutive androstane receptor (internal sequence). The exact sequence is proprietary. Database link: Q14994

Positive control WB: Mouse liver lysate.

General notes: The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase.

Function: binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element.

Tissue specificity: predominantly expressed in liver.

Supplementary material 7 – S7

Sequence similarities: belongs to the nuclear hormone receptor family. NR1 subfamily. Contains 1 nuclear receptor DNA-binding domain.

Domain: composed by a short N-terminal domain followed by the DNA binding, hinge, and ligand binding/dimerization domains.

Post-translational modifications: Phosphorylated at Thr-38 by PKC, dephosphorylation of Thr-38 is required for nuclear translocation and activation.

Cellular localization: nucleus. Cytoplasm. Cytoplasm > cytoskeleton. Recruited to the cytoplasm by DNAJC7.

Predicted band size: 40 kDa

16. Rabbit polyclonal anti-aromatase antibody (ab-18995)

Product name: Anti-Aromatase antibody

Description: Rabbit polyclonal to Aromatase

Host species: Rabbit

Tested applications: suitable for: IHC-P, ICC/IF, IHC-Fr, WBmore details

Species reactivity: reacts with: Mouse, Rat, Human

Predicted to work with: Chicken, Cow, Pig

Immunogen: synthetic peptide surrounding amino acid 385 of human Aromatase (Peptide available as ab51924.)

General notes: The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.

Function: catalyzes the formation of aromatic C18 estrogens from C19 androgens.

Tissue specificity: brain, placenta and gonads.

Involvement in disease: defects in CYP19A1 are a cause of aromatase excess syndrome (AEXS) [MIM:139300]; also known as familial gynecomastia. AEXS is characterized by an estrogen excess due to an increased aromatase activity. Defects in CYP19A1 are the cause of aromatase deficiency (AROD) [MIM:107910]. AROD is a rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of external genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.

Sequence similarities: belongs to the cytochrome P450 family.

Cellular localization: membrane.

Predicted band size: 58 kDa

Observed band size: 58 kDa

Additional bands at: 34 kDa. Supplier is unsure as to the identity of these extra bands.